한빛사 논문
Abstract
Jung Hun Kang, Soon Il Lee, Do Hyoung Lim, Keon-Woo Park, Sung Yong Oh, Hyuk-Chan Kwon, In Gyu Hwang, Sang-Cheol Lee, Eunmi Nam, Dong Bok Shin, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang and Se Hoon Park*
Jung Hun Kang, Gyeongsang National University Hospital, Jinju; Soon Il Lee, Do Hyoung Lim, and Keon-Woo Park, Dankook University Hospital, Cheonan; Sung Yong Oh and Hyuk-Chan Kwon, Dong-A University Hospital, Busan; In Gyu Hwang, Chung-Ang University College of Medicine; Sang-Cheol Lee, Soonchunhyang University Hospital; Eunmi Nam, Ewha Women's University Hospital; Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, and Se Hoon Park, Sungkyunkwan University Samsung Medical Center, Seoul; and Dong Bok Shin, Gachon University Gil Hospital, Incheon, Korea.
*Corresponding author: Se Hoon Park, MD, Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul 135-710, Korea
Abstract
Purpose When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted in substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients with AGC for anecdotal reasons.
Patients and Methods Patients with AGC with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum and with an Eastern Cooperative Oncology Group performance status (PS) 0 or 1 were randomly assigned in a ratio of 2:1 to SLC plus BSC or BSC alone. Choice of SLC-either docetaxel 60 mg/m2 every 3 weeks or irinotecan 150 mg/m2 every 2 weeks-was left to the discretion of investigators. Primary end point was overall survival (OS).
Results Median OS was 5.3 months among 133 patients in the SLC arm and 3.8 months among 69 patients in the BSC arm (hazard ratio, 0.657; 95% CI, 0.485 to 0.891; one-sided P = .007). OS benefit for SLC was consistent in most of the prospectively defined subgroups, including age, PS, number of prior treatments, metastatic sites, hemoglobin levels, and response to prior chemotherapy. SLC was generally well tolerated, and adverse events were similar in the SLC and BSC arms. We found no median OS difference between docetaxel and irinotecan (5.2 v 6.5 months; P = .116).
Conclusion To our knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC. In pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기